The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: A prospective, multicenter, double-blinded, randomized, placebo-controlled trial

Michael G L Sarr, Eugene A. Woltering

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

BACKGROUND: Pancreatectomy can be complicated by pancreatic anastomotic leakage, causing major morbidity. STUDY DESIGN: Our aim was to determine if vapreotide, a potent long-acting somatostatin analogue, would decrease pancreas-related complications. This prospective, multicenter, randomized, doubleblind, placebo-controlled trial involved 275 patients without preexisting chronic pancreatitis undergoing elective proximal, central, or distal pancreatectomy. Complications were defined by objective criteria before beginning the study. RESULTS: One hundred thirty-five patients received vapreotide; 140 patients received placebo. There were no statistically significant differences between vapreotide- and placebo-treated patients in either pancreas-related complications (30.4% versus 26.4%, respectively) or in other complications not directly related to the pancreas (40% versus 42%, respectively). CONCLUSIONS: The potent somatostatin analogue vapreotide does not appear to decrease postoperative complications after major pancreatectomy in patients without chronic pancreatitis.

Original languageEnglish (US)
Pages (from-to)556-565
Number of pages10
JournalJournal of the American College of Surgeons
Volume196
Issue number4
DOIs
StatePublished - Apr 1 2003

Fingerprint

Pancreatectomy
Somatostatin
Pancreas
Randomized Controlled Trials
Placebos
Chronic Pancreatitis
Anastomotic Leak
vapreotide
Morbidity

ASJC Scopus subject areas

  • Surgery

Cite this

@article{466dd9fc55f5487a810d4e3e47aa2c20,
title = "The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: A prospective, multicenter, double-blinded, randomized, placebo-controlled trial",
abstract = "BACKGROUND: Pancreatectomy can be complicated by pancreatic anastomotic leakage, causing major morbidity. STUDY DESIGN: Our aim was to determine if vapreotide, a potent long-acting somatostatin analogue, would decrease pancreas-related complications. This prospective, multicenter, randomized, doubleblind, placebo-controlled trial involved 275 patients without preexisting chronic pancreatitis undergoing elective proximal, central, or distal pancreatectomy. Complications were defined by objective criteria before beginning the study. RESULTS: One hundred thirty-five patients received vapreotide; 140 patients received placebo. There were no statistically significant differences between vapreotide- and placebo-treated patients in either pancreas-related complications (30.4{\%} versus 26.4{\%}, respectively) or in other complications not directly related to the pancreas (40{\%} versus 42{\%}, respectively). CONCLUSIONS: The potent somatostatin analogue vapreotide does not appear to decrease postoperative complications after major pancreatectomy in patients without chronic pancreatitis.",
author = "Sarr, {Michael G L} and Woltering, {Eugene A.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S1072-7515(03)00104-2",
language = "English (US)",
volume = "196",
pages = "556--565",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy

T2 - A prospective, multicenter, double-blinded, randomized, placebo-controlled trial

AU - Sarr, Michael G L

AU - Woltering, Eugene A.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - BACKGROUND: Pancreatectomy can be complicated by pancreatic anastomotic leakage, causing major morbidity. STUDY DESIGN: Our aim was to determine if vapreotide, a potent long-acting somatostatin analogue, would decrease pancreas-related complications. This prospective, multicenter, randomized, doubleblind, placebo-controlled trial involved 275 patients without preexisting chronic pancreatitis undergoing elective proximal, central, or distal pancreatectomy. Complications were defined by objective criteria before beginning the study. RESULTS: One hundred thirty-five patients received vapreotide; 140 patients received placebo. There were no statistically significant differences between vapreotide- and placebo-treated patients in either pancreas-related complications (30.4% versus 26.4%, respectively) or in other complications not directly related to the pancreas (40% versus 42%, respectively). CONCLUSIONS: The potent somatostatin analogue vapreotide does not appear to decrease postoperative complications after major pancreatectomy in patients without chronic pancreatitis.

AB - BACKGROUND: Pancreatectomy can be complicated by pancreatic anastomotic leakage, causing major morbidity. STUDY DESIGN: Our aim was to determine if vapreotide, a potent long-acting somatostatin analogue, would decrease pancreas-related complications. This prospective, multicenter, randomized, doubleblind, placebo-controlled trial involved 275 patients without preexisting chronic pancreatitis undergoing elective proximal, central, or distal pancreatectomy. Complications were defined by objective criteria before beginning the study. RESULTS: One hundred thirty-five patients received vapreotide; 140 patients received placebo. There were no statistically significant differences between vapreotide- and placebo-treated patients in either pancreas-related complications (30.4% versus 26.4%, respectively) or in other complications not directly related to the pancreas (40% versus 42%, respectively). CONCLUSIONS: The potent somatostatin analogue vapreotide does not appear to decrease postoperative complications after major pancreatectomy in patients without chronic pancreatitis.

UR - http://www.scopus.com/inward/record.url?scp=0037388767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037388767&partnerID=8YFLogxK

U2 - 10.1016/S1072-7515(03)00104-2

DO - 10.1016/S1072-7515(03)00104-2

M3 - Article

C2 - 12691930

AN - SCOPUS:0037388767

VL - 196

SP - 556

EP - 565

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 4

ER -